Global Antidiabetic Glucagon-like Peptide 1 Agonists Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Page: 91
Published Date: 05 Jan 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Antidiabetic Glucagon-like Peptide 1 Agonists market size was valued at USD 5543 million in 2023 and is forecast to a readjusted size of USD 7350.8 million by 2030 with a CAGR of 4.1% during review period.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
The Global Info Research report includes an overview of the development of the Antidiabetic Glucagon-like Peptide 1 Agonists industry chain, the market status of Hospital (Exenatied, Liraglutide), Pharmacy (Exenatied, Liraglutide), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Antidiabetic Glucagon-like Peptide 1 Agonists.
Regionally, the report analyzes the Antidiabetic Glucagon-like Peptide 1 Agonists markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Antidiabetic Glucagon-like Peptide 1 Agonists market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Antidiabetic Glucagon-like Peptide 1 Agonists market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Antidiabetic Glucagon-like Peptide 1 Agonists industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Exenatied, Liraglutide).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Antidiabetic Glucagon-like Peptide 1 Agonists market.
Regional Analysis: The report involves examining the Antidiabetic Glucagon-like Peptide 1 Agonists market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Antidiabetic Glucagon-like Peptide 1 Agonists market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Antidiabetic Glucagon-like Peptide 1 Agonists:
Company Analysis: Report covers individual Antidiabetic Glucagon-like Peptide 1 Agonists manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Antidiabetic Glucagon-like Peptide 1 Agonists This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Pharmacy).
Technology Analysis: Report covers specific technologies relevant to Antidiabetic Glucagon-like Peptide 1 Agonists. It assesses the current state, advancements, and potential future developments in Antidiabetic Glucagon-like Peptide 1 Agonists areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Antidiabetic Glucagon-like Peptide 1 Agonists market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Antidiabetic Glucagon-like Peptide 1 Agonists market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market segment by Application
Hospital
Pharmacy
Major players covered
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antidiabetic Glucagon-like Peptide 1 Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, with price, sales, revenue and global market share of Antidiabetic Glucagon-like Peptide 1 Agonists from 2019 to 2024.
Chapter 3, the Antidiabetic Glucagon-like Peptide 1 Agonists competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antidiabetic Glucagon-like Peptide 1 Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Antidiabetic Glucagon-like Peptide 1 Agonists market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Antidiabetic Glucagon-like Peptide 1 Agonists.
Chapter 14 and 15, to describe Antidiabetic Glucagon-like Peptide 1 Agonists sales channel, distributors, customers, research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Antidiabetic Glucagon-like Peptide 1 Agonists
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Exenatied
1.3.3 Liraglutide
1.3.4 Lixisenatide
1.3.5 Albiglutide
1.3.6 Dulaglutide
1.4 Market Analysis by Application
1.4.1 Overview: Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Pharmacy
1.5 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size & Forecast
1.5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (2019-2030)
1.5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (2019-2030)
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.1.4 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Novo Nordisk Recent Developments/Updates
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.2.4 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 AstraZeneca Recent Developments/Updates
2.3 Eli Lily
2.3.1 Eli Lily Details
2.3.2 Eli Lily Major Business
2.3.3 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.3.4 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Eli Lily Recent Developments/Updates
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business
2.4.3 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.4.4 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 GSK Recent Developments/Updates
2.5 Sanofi
2.5.1 Sanofi Details
2.5.2 Sanofi Major Business
2.5.3 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.5.4 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Sanofi Recent Developments/Updates
2.6 Bristol-Myers Squibb
2.6.1 Bristol-Myers Squibb Details
2.6.2 Bristol-Myers Squibb Major Business
2.6.3 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.6.4 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Bristol-Myers Squibb Recent Developments/Updates
2.7 Abbott Laboratories
2.7.1 Abbott Laboratories Details
2.7.2 Abbott Laboratories Major Business
2.7.3 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
2.7.4 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Abbott Laboratories Recent Developments/Updates
3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Manufacturer (2019-2024)
3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Manufacturer (2019-2024)
3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Antidiabetic Glucagon-like Peptide 1 Agonists by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer Market Share in 2023
3.4.2 Top 6 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer Market Share in 2023
3.5 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Overall Company Footprint Analysis
3.5.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Region Footprint
3.5.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Type Footprint
3.5.3 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region
4.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2019-2030)
4.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2019-2030)
4.1.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2019-2030)
4.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030)
4.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030)
4.4 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030)
4.5 South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030)
4.6 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030)
5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2030)
5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type (2019-2030)
5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2019-2030)
6.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2030)
6.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application (2019-2030)
6.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2019-2030)
7.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2030)
7.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2030)
7.3 North America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
7.3.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2019-2030)
7.3.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2030)
8.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2030)
8.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
8.3.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2019-2030)
8.3.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region
9.3.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10.1 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2030)
10.2 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2030)
10.3 South America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
10.3.1 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2019-2030)
10.3.2 South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
11.3.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
12.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
12.3 Antidiabetic Glucagon-like Peptide 1 Agonists Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13.1 Raw Material of Antidiabetic Glucagon-like Peptide 1 Agonists and Key Manufacturers
13.2 Manufacturing Costs Percentage of Antidiabetic Glucagon-like Peptide 1 Agonists
13.3 Antidiabetic Glucagon-like Peptide 1 Agonists Production Process
13.4 Antidiabetic Glucagon-like Peptide 1 Agonists Industrial Chain
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Distributors
14.3 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Customers
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk Major Business
Table 5. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
Table 6. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Novo Nordisk Recent Developments/Updates
Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 9. AstraZeneca Major Business
Table 10. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
Table 11. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. AstraZeneca Recent Developments/Updates
Table 13. Eli Lily Basic Information, Manufacturing Base and Competitors
Table 14. Eli Lily Major Business
Table 15. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
Table 16. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Eli Lily Recent Developments/Updates
Table 18. GSK Basic Information, Manufacturing Base and Competitors
Table 19. GSK Major Business
Table 20. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
Table 21. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. GSK Recent Developments/Updates
Table 23. Sanofi Basic Information, Manufacturing Base and Competitors
Table 24. Sanofi Major Business
Table 25. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
Table 26. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Sanofi Recent Developments/Updates
Table 28. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 29. Bristol-Myers Squibb Major Business
Table 30. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
Table 31. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Bristol-Myers Squibb Recent Developments/Updates
Table 33. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 34. Abbott Laboratories Major Business
Table 35. Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
Table 36. Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Abbott Laboratories Recent Developments/Updates
Table 38. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 39. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Manufacturer (2019-2024) & (USD Million)
Table 40. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 41. Market Position of Manufacturers in Antidiabetic Glucagon-like Peptide 1 Agonists, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 42. Head Office and Antidiabetic Glucagon-like Peptide 1 Agonists Production Site of Key Manufacturer
Table 43. Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Type Footprint
Table 44. Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Application Footprint
Table 45. Antidiabetic Glucagon-like Peptide 1 Agonists New Market Entrants and Barriers to Market Entry
Table 46. Antidiabetic Glucagon-like Peptide 1 Agonists Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2019-2024) & (K Units)
Table 48. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2025-2030) & (K Units)
Table 49. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2019-2024) & (USD Million)
Table 50. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2025-2030) & (USD Million)
Table 51. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2019-2024) & (US$/Unit)
Table 52. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2025-2030) & (US$/Unit)
Table 53. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2024) & (K Units)
Table 54. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2025-2030) & (K Units)
Table 55. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type (2019-2024) & (USD Million)
Table 56. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type (2025-2030) & (USD Million)
Table 57. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2019-2024) & (US$/Unit)
Table 58. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2025-2030) & (US$/Unit)
Table 59. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2024) & (K Units)
Table 60. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2025-2030) & (K Units)
Table 61. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application (2019-2024) & (USD Million)
Table 62. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application (2025-2030) & (USD Million)
Table 63. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2019-2024) & (US$/Unit)
Table 64. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2025-2030) & (US$/Unit)
Table 65. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2024) & (K Units)
Table 66. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2025-2030) & (K Units)
Table 67. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2024) & (K Units)
Table 68. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2025-2030) & (K Units)
Table 69. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2019-2024) & (K Units)
Table 70. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2025-2030) & (K Units)
Table 71. North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2019-2024) & (USD Million)
Table 72. North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2025-2030) & (USD Million)
Table 73. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2024) & (K Units)
Table 74. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2025-2030) & (K Units)
Table 75. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2024) & (K Units)
Table 76. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2025-2030) & (K Units)
Table 77. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2019-2024) & (K Units)
Table 78. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2025-2030) & (K Units)
Table 79. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2019-2024) & (USD Million)
Table 80. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2025-2030) & (USD Million)
Table 81. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2024) & (K Units)
Table 82. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2025-2030) & (K Units)
Table 83. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2024) & (K Units)
Table 84. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2025-2030) & (K Units)
Table 85. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2019-2024) & (K Units)
Table 86. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2025-2030) & (K Units)
Table 87. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2019-2024) & (USD Million)
Table 88. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2025-2030) & (USD Million)
Table 89. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2024) & (K Units)
Table 90. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2025-2030) & (K Units)
Table 91. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2024) & (K Units)
Table 92. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2025-2030) & (K Units)
Table 93. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2019-2024) & (K Units)
Table 94. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2025-2030) & (K Units)
Table 95. South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2019-2024) & (USD Million)
Table 96. South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2025-2030) & (USD Million)
Table 97. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2019-2024) & (K Units)
Table 98. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2025-2030) & (K Units)
Table 99. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2019-2024) & (K Units)
Table 100. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2025-2030) & (K Units)
Table 101. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2019-2024) & (K Units)
Table 102. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2025-2030) & (K Units)
Table 103. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2019-2024) & (USD Million)
Table 104. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2025-2030) & (USD Million)
Table 105. Antidiabetic Glucagon-like Peptide 1 Agonists Raw Material
Table 106. Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists Raw Materials
Table 107. Antidiabetic Glucagon-like Peptide 1 Agonists Typical Distributors
Table 108. Antidiabetic Glucagon-like Peptide 1 Agonists Typical Customers
List of Figures
Figure 1. Antidiabetic Glucagon-like Peptide 1 Agonists Picture
Figure 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Type in 2023
Figure 4. Exenatied Examples
Figure 5. Liraglutide Examples
Figure 6. Lixisenatide Examples
Figure 7. Albiglutide Examples
Figure 8. Dulaglutide Examples
Figure 9. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 10. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Application in 2023
Figure 11. Hospital Examples
Figure 12. Pharmacy Examples
Figure 13. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (2019-2030) & (K Units)
Figure 16. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (2019-2030) & (US$/Unit)
Figure 17. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of Antidiabetic Glucagon-like Peptide 1 Agonists by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 20. Top 3 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Top 6 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer (Consumption Value) Market Share in 2023
Figure 22. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Region (2019-2030)
Figure 24. North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030) & (USD Million)
Figure 27. South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2019-2030) & (USD Million)
Figure 29. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Type (2019-2030)
Figure 31. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2019-2030) & (US$/Unit)
Figure 32. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Application (2019-2030)
Figure 34. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2019-2030) & (US$/Unit)
Figure 35. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Country (2019-2030)
Figure 39. United States Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Canada Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Mexico Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. France Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. United Kingdom Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Russia Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Italy Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Region (2019-2030)
Figure 55. China Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Japan Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Korea Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. India Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Southeast Asia Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Australia Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Argentina Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 67. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Region (2019-2030)
Figure 70. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Region (2019-2030)
Figure 71. Turkey Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Egypt Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Saudi Arabia Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. South Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
Figure 76. Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
Figure 77. Antidiabetic Glucagon-like Peptide 1 Agonists Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Antidiabetic Glucagon-like Peptide 1 Agonists in 2023
Figure 80. Manufacturing Process Analysis of Antidiabetic Glucagon-like Peptide 1 Agonists
Figure 81. Antidiabetic Glucagon-like Peptide 1 Agonists Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Novo Nordisk AstraZeneca Eli Lily GSK Sanofi Bristol-Myers Squibb Abbott Laboratories
Related Reports
06 Feb 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
